ExpreS2ion to Host Q2 2026 Half-Year Report Presentation and Participate in Morgenbørs Live Podcast Interview

These events provide an opportunity to present ExpreS2ion’s technology platform and development pipeline to investors and industry participants. More details, including event registration information, are available on the Company’s website and via the links below. To arrange a meeting at these events, please contact us at partnering@expres2ionbio.com or investor@expres2ionbio.com.

20 August 2026 | Q2 2026 Half-Year Report Presentation
Virtual, 10:00 CET
CEO Bent Frandsen and CFO Keith Alexander will present ExpreS2ion’s Q2 2026 half-year report at a virtual investor event hosted by H.C. Andersen Capital. The presentation will cover the Company’s clinical progress, partnered programmes, platform activities and financial position.

Investors may register for the webcast and submit questions in advance via the Inderes platform. The event is free and open to all investors.

25 August 2026 | Morgenbørs Live Podcast Interview with CEO Bent Frandsen
Virtual, 8:50 CET
CEO Bent Frandsen will join Morgenbørs, H.C. Andersen Capital's daily live podcast covering Danish and US equities, for a short interview broadcast live from 8:50 to 8:55 CEST on 25 August 2026.

The interview, conducted in Danish, will give investors a brief update hon ExpreS2ion's recent developments and key priorities. Morgenbørs is hosted by H.C. Andersen Capital's analyst team and broadcast live via LinkedIn, Facebook, X and the Aktieporteføljen community. A recording will be available afterwards on podcast platforms and via inderes.dk. The event is free and open to all investors.

Certified Adviser
Redeye Nordic Growth AB

For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com

About ExpreS2ion
ExpreS2ion is a biotechnology company focused on the development of innovative active immunotherapies and vaccines for cancer and infectious diseases. The company has developed the ExpreS2™ platform, a proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle (VLP) projects spanning research, diagnostics, and therapeutic development. Proteins produced using the ExpreS2 platform are being evaluated in multiple clinical programmes worldwide. The platform has also been applied in partnered development programmes that have progressed into late-stage clinical evaluation, including Phase III studies that have met their primary endpoints. The platform, marketed as GlycoX-S2™, includes functionally modified glycosylation variants designed to enhance immunogenicity and pharmacokinetics. ExpreS2ion develops novel VLP-based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. ExpreS2ion Biotech Holding AB is listed on Nasdaq First North Growth Market. For additional information, please visit www.expres2ionbio.com.